Stem Cell Clinic

Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

By Global News Feed

CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) --  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the nomination of BDTX-1535 as the Company’s development candidate for the treatment of glioblastoma multiforme (GBM), as well as the commencement of Investigational New Drug (IND)-enabling studies.

See the original post here:
Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

By Global News Feed

MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

See the original post:
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

By Global News Feed

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

Excerpt from:
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

By Global News Feed

NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that it will host an expert panel on acromegaly and the results from its recently completed MPOWERED® Phase 3 clinical trial on Monday, November 30, 2020 at 11:00 am Eastern Time.

Read the original:
Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference

By Global News Feed

RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 32nd Annual Healthcare Conference.

More here:
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders

By Global News Feed

WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) -- NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors.

Follow this link:
Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders

Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

By Global News Feed

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the launch of a dedicated website for its affiliate Altamira Medica Ltd. The website, www.altamiramedica.com, offers quick and easy access to information about the Company’s development of AM-301, a drug-free nasal spray intended for self-protection against risks from exposure to airborne viruses and allergens.

Read more from the original source:
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

Chalice Farms to Launch “Holiday in Color” Pre-Roll Packs, Festive Promotions through Holiday Season

By Global News Feed

PORTLAND, Ore., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE:GLH) (OTCQB:GLDFF) (“Golden Leaf” or the “Company”), a premier, consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, announces that Chalice Farms, a wholly owned subsidiary of Golden Leaf, will spread holiday cheer by launching a “Holiday in Color” pre-roll pack, along with weekly promotions and specials through the holidays, available now.

Read more:
Chalice Farms to Launch “Holiday in Color” Pre-Roll Packs, Festive Promotions through Holiday Season

LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering

By Global News Feed

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering of 7,500,000 shares at $10.00 per share. The shares will begin trading today on the NASDAQ Capital Market (“NASDAQ”) under the symbol “LSAQ.”

Read the original:
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering

→←